Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Tannock, Ian F., de Wit, Ronald, Berry, William R., Horti, Jozsef, Pluzanska, Anna, Chi, Kim N., Oudard, Stephane, Théodore, Christine +4 more·2004·New England Journal of Medicine

DOI 10.1056/nejmoa040720

Cited by (1,006)

Items 901–1,000 of 1,006

Glycans and galectins in prostate cancer biology, angiogenesis and metastasis
Daniel Compagno, Lucas D. Gentilini, Felipe Martín Jaworski, Ignacio González Pérez, Geraldine Contrufo, Diego J. Laderach · 2014 · Glycobiology
New agents for prostate cancer
N. Agarwal, Giuseppe Di Lorenzo, Guru Sonpavde, Joaquim Bellmunt B · 2014 · Annals of Oncology
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
Jan Kroon, Martin Puhr, Jeroen T. Buijs, Geertje van der Horst, Danielle M. Hemmer, Koen A. Marijt, Ming‐Shih Hwang, Motasim Masood, Stefan Grimm, Gert Storm et al. · 2015 · Endocrine Related Cancer
Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer
Diane Ojo, Xiaozeng Lin, Nicholas Wong, Yan Jennifer Gu, Damu Tang · 2015 · Cancers
AR-V7 and prostate cancer: The watershed for treatment selection?
Chiara Ciccarese, Matteo Santoni, Matteo Brunelli, Sebastiano Buti, Alessandra Modena, Massimo Nabissi, Walter Artibani, Guido Martignoni, Rodolfo Montironi, Giampaolo Tortora et al. · 2015 · Cancer Treatment Reviews
Multiparametric liquid biopsy analysis in metastatic prostate cancer
Emmanuelle Hodara, Gareth J. Morrison, Alexander T. Cunha, Daniel E. Zainfeld, Tong Xu, Yucheng Xu, Paul W. Dempsey, Paul C. Pagano, Farideh Z. Bischoff, Aditi Khurana et al. · 2019 · JCI Insight
Investigating the Multi-Target Pharmacological Mechanism of Hedyotis diffusa Willd Acting on Prostate Cancer: A Network Pharmacology Approach
Yanan Song, Haiyan Wang, Yajing Pan, Tonghua Liu · 2019 · Biomolecules
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen
Harshad Kulkarni, Aviral Singh, Thomas Langbein, Christiane Schuchardt, Dirk Müeller, Jingjing Zhang, Coline Lehmann, Richard Paul Baum · 2018 · British Journal of Radiology
An ex vivo Tissue Culture Model for the Assessment of Individualized Drug Responses in Prostate and Bladder Cancer
Arjanneke F. van de Merbel, Geertje van der Horst, Maaike H. van der Mark, Janneke I. M. van Uhm, Erik J. van Gennep, Peter Kloen, Lijkele Beimers, Rob C.M. Pelger, Gabri van der Pluijm · 2018 · Frontiers in Oncology
Exosomes are the Driving Force in Preparing the Soil for the Metastatic Seeds: Lessons from the Prostate Cancer
Saber H. Saber, Hamdy E. Abouzeid Ali, Rofaida Gaballa, Mohamed S. A. Gaballah, Hamed Ismail Ali, Mourad Zerfaoui, Zakaria Y. Abd Elmageed · 2020 · Cells
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
Judith Passildas, Jean‐Christophe Eymard, Mélanie Pouget, Fabrice Kwiatkowski, Isabelle Van Praagh, Laurent Savareux, Marc Atger, Xavier Durando, Catherine Abrial, Damien Richard et al. · 2021 · Cancer Medicine
Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
Florian Rosar, Jonas Krause, Mark Daniel Bartholomä, Stephan Maus, Tobias Stemler, Ina Hierlmeier, Johannes Linxweiler, Samer Ezziddin, Fadi Khreish · 2021 · Pharmaceutics
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
Mark T. Fleming, Michael J. Morris, Glenn Heller, Howard I. Scher · 2006 · Nature Clinical Practice Oncology
Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells
Melissa A. Babcook, R. Michael Sramkoski, Hisashi Fujioka, Firouz Daneshgari, Alexandru Almasan, Sandeep Shukla, R R Nanavaty, Sanjay Gupta · 2014 · Cell Death and Disease
Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl‐2 and Bcl‐xL genes
Kazuki Yamanaka, Palma Rocchi, Hideaki Miyake, Ladan Fazli, Alan So, Uwe Zangemeister‐Wittke, Martin Edwin Gleave · 2006 · British Journal of Urology
Nuclear factor‐kappa B and interleukin‐6 related docetaxel resistance in castration‐resistant prostate cancer
Jordi Codony‐Servat, Mercedes Marín‐Aguilera, Laura Visa, Xabier García‐Albéniz, Estela Pineda, Pedro Luis Fernández, Xavier Filella, Pere Gascón, Begoña Mellado · 2012 · The Prostate
Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project
Joanne L. Lord, Sarah Willis, Julie Eatock, Paul Tappenden, Marta Trapero‐Bertran, Alec H. Miners, Catriona Crossan, Maggie J Westby, Anastasia Anagnostou, Simon J. E. Taylor et al. · 2013 · Health Technology Assessment
Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential
Giuseppe Galletti, Luigi Portella, Scott T. Tagawa, Brian J. Kirby, Paraskevi Giannakakou, David M. Nanus · 2014 · Molecular Diagnosis & Therapy
Docetaxel
Kate McKeage · 2012 · Drugs
Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer
Steven Attia, Jens C. Eickhoff, George Wilding, Douglas G. McNeel, Jules H. Blank, Harish G. Ahuja, Alcee J. Jumonville, Michael E. Eastman, Daniel H. Shevrin, Michael Glodé et al. · 2008 · Clinical Cancer Research
Pre-Treatment Nomogram for Disease-Specific Survival of Patients with Chemotherapy-Naive Androgen Independent Prostate Cancer
Robert Scott Svatek, Pierre I. Karakiewicz, Michael J. Shulman, Jose Antonio Karam, Paul Perrotte, Elie A. Benaim · 2006 · European Urology
Treatment evolution for metastatic castration‐resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real‐world data
Thomas W. Flaig, Ravi C. Potluri, Yvette Ng, Mary Beth Todd, Maneesha Mehra · 2015 · Cancer Medicine
Galeterone for the treatment of advanced prostate cancer: the evidence to date
Emmanuel S. Antonarakis, Diogo Assed Bastos · 2016 · Drug Design Development and Therapy
Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
Vipin Lohiya, Jeanny B. Aragon‐Ching, Guru Sonpavde · 2016 · Clinical Medicine Insights Oncology
Disparities in prostate cancer incidence and mortality rates: Solvable or not?
Simone Ann Marie Badal, William Derval Aiken, Belinda F. Morrison, Henkel Valentine, Sophia Bryan, Andrew Gachii, Camille C. Rose Ragin · 2019 · The Prostate
Clinical outcome of maximum androgen blockade using flutamide as second‐line hormonal therapy for hormone‐refractory prostate cancer
Hideaki Miyake, Isao Hara, Hiroshi Eto · 2005 · British Journal of Urology
Future directions in the treatment of androgen-independent prostate cancer
Daniel Peter Petrylak · 2005 · Urology
Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells
Camille Loubière, Thomas Goiran, Kathiane Laurent, Zied Djabari, Jean‐François Tanti, Frédéric Bost · 2015 · Oncotarget
Neoadjuvant docetaxel treatment for locally advanced prostate cancer
Cristina Magi‐Galluzzi, Ming Zhou, Alwyn M. Reuther, Robert Dreicer, Eric A. Klein · 2007 · Cancer
Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study
Sophie D. Fosså, Anne-Birgitte Jacobsen, Claes Ginman, Inga N. Jacobsen, Sissel Overn, Jon Reidar Iversen, Thomas Urnes, Alv Andreas Dahl, Marijke Veenstra, Berit Sandstad · 2007 · European Urology
Cancer/testis antigens and urological malignancies
Prakash Kulkarni, Takumi Shiraishi, Krithika Rajagopalan, Robert Kim, Steven M. Mooney, Robert H. Getzenberg · 2012 · Nature Reviews Urology
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid
Todd Matthew Morgan, Tiffany E.M. Pitts, Ted S. Gross, Sandra L. Poliachik, Robert L. Vessella, Eva Corey · 2008 · The Prostate
Successful Treatment of Metastatic Androgen-Independent Prostate Carcinoma in a Transsexual Patient
Tanya Barauskas Dorff, Ronald L. Shazer, Edward Macrohon Nepomuceno, Steven J. Tucker · 2007 · Clinical Genitourinary Cancer
Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer
Wytske M. van Weerden, Chris H. Bangma, Ronald de Wit · 2008 · British Journal of Cancer
The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature
Guru Sonpavde, Gerhardt Attard, Joaquim Bellmunt B, Malcolm David Mason, Bernard A. Malavaud, Bertrand F. TOMBAL, Cora Nanette Sternberg · 2011 · European Urology
Modulation of Protein Phosphatase 2A Activity Alters Androgen-Independent Growth of Prostate Cancer Cells: Therapeutic Implications
Arun Bhardwaj, Seema Singh, Sanjeev K. Srivastava, Richard E. Honkanen, Eddie Reed, Ajay P. Singh · 2011 · Molecular Cancer Therapeutics
Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients
Christina Bæksted, Helle Pappot, Aase Nissen, Niels Henrik Hjøllund, Sandra A. Mitchell, Ethan Basch, Pernille Envold Bidstrup, Susanne Oksbjerg Dalton, Christoffer Johansen · 2017 · Journal of Patient-Reported Outcomes
Fighting tubulin-targeting anticancer drug toxicity and resistance
Roberta Visconti, Domenico Grieco · 2017 · Endocrine Related Cancer
Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells
Patricia M. Schnepp, Greg Shelley, Jinlu Dai, Nicole I. Wakim, Hui Jiang, Atsushi Mizokami, Evan T. Keller · 2020 · Molecular Cancer Research
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
Johanna Maffey-Steffan, Lorenza Scarpa, Anna Svirydenka, Bernhard Nilica, Christian Mair, Sabine Buxbaum, Jasmin Bektić, Elisabeth von Guggenberg, Christian Uprimny, Wolfgang Horninger et al. · 2019 · European Journal of Nuclear Medicine and Molecular Imaging
Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study
Robert J. van Soest, Ellen S. de Morrée, Liji Shen, Ian F. Tannock, Mario A. Eisenberger, Ronald de Wit · 2013 · European Urology
Systems Biology: A Therapeutic Target for Tumor Therapy
Albrecht Reichle, THOMAS M. VOGT · 2008 · Cancer Microenvironment
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
Marco Moschini, Martin Spahn, Agostino Mattei, John C. Cheville, Robert Jeffrey Karnes · 2016 · BMC Medicine
Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis
Sascha D. Markowitsch, Kira M. Juetter, Patricia Schupp, Kristine Hauschulte, Olesya Vakhrusheva, Kimberly Sue Slade, Anita Thomas, Igor Tsaur, Jindrich Jr. Cinatl, Martin Michaelis et al. · 2021 · Cancers
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Mike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, Christoph Würnschimmel, Zhe Tian, Shahrokh François Shariat, Fred Saad C, Derya Tilki, Markus Graefen, Luis Alex Kluth et al. · 2021 · Prostate Cancer and Prostatic Diseases
Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer
Prabhakar Rajan, Jacqueline Stockley, Ian M. Sudbery, Janis Fleming, Ann Hedley, Gabriela Kalna, David Sims, Chris Paul Ponting, Andreas Heger, Craig N. Robson et al. · 2014 · BMC Cancer
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells
Pedram Kharaziha, Patricia Q. Rodriguez, Qiao Li, Helene Rundqvist, A-C Björklund, Martin Augsten, Anders Ullén, Lars Egevad, Peter N. Wiklund, Sten F. Nilsson et al. · 2012 · Cell Death and Disease
Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer
Sergio Ricci, Giuseppe Boni, Ilaria Pastina, Dario Genovesi, Claudia Cianci, Serena Chiacchio, Cinzia Orlandini, Mariano Grosso, Abedallatif A. AlSharif, Aldo Chioni et al. · 2007 · European Journal of Nuclear Medicine and Molecular Imaging
Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary
Yangmin M. Ning, William F. Pierce, Virginia Ellen Maher, Stella Wanjugu Karuri, Shenghui W. Tang, Haw-Jyh Chiu, Todd R. Palmby, Jeanne Fourie Zirkelbach, Dhananjay D. Marathe, Nitin Mehrotra et al. · 2013 · Clinical Cancer Research
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
Che‐Kai Tsao, Elena Cutting, Jacob Andrew Martin, William K. Oh · 2014 · Therapeutic Advances in Urology
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
Johann Sebastian De Bono, L. Rhoda Molife, Guru Sonpavde, Pablo Maroto, Emiliano Calvo, Thomas H. Cartwright, David M. Loesch, Kevie Feit, A. Das, E. Zang et al. · 2011 · Annals of Oncology
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
Mustafa Khasraw, Nick Pavlakis, S. McCowatt, Craig R. Underhill, Stephen D. Begbie, Paul DE SOUZA, Adam Boyce, Francis X. Parnis, Victoria M. M. Lim, Rozelle M. Harvie et al. · 2009 · Annals of Oncology
Molecular landscape of prostate cancer: Implications for current clinical trials
Galina Khemlina, Sadakatsu Ikeda, Razelle Kurzrock · 2015 · Cancer Treatment Reviews
Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer
Yun Fei Xia, Chiang‐Ching Huang, Rachel L. Dittmar, Meijun Du, Yuan Wang, Hongyan Liu, Niraj Konchady Shenoy, Liang Wang, Manish Kohli · 2016 · Oncotarget
MicroRNAs and epithelial-mesenchymal transition in prostate cancer
Kirandeep Sekhon, Nathan Bucay, Shahana Majid, Rajvir Dahiya, Sharanjot Saini · 2016 · Oncotarget
miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression
Balabhadrapatruni V. S. K. Chakravarthi, Darshan Shimoga Chandrashekar, Sumit Agarwal, Sai Akshaya Hodigere Balasubramanya, Satya S. Pathi, Moloy T. Goswami, Xiaojun Jing, Rui Wang, Rohit Mehra, Irfan Ahmed Asangani et al. · 2017 · Molecular Cancer Research
Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
Ellen Wargowski, Laura E. Johnson, Jens C. Eickhoff, Lauren E Delmastro, Mary Jane Staab, Glenn Liu, Douglas G. McNeel · 2018 · Journal for ImmunoTherapy of Cancer
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint
Ethan Basch, Mark Creamer Scholz, Johann Sebastian De Bono, Nicholas J. Vogelzang, Paul DE SOUZA, Gavin M. Marx, Ulka N. Vaishampayan, Saby George, James K. Schwarz, Emmanuel S. Antonarakis et al. · 2018 · European Urology
Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
Ke Li, Wenhua Zhan, Yulong Chen, Rajiv Kumar Jha, Xueli Chen · 2019 · Frontiers in Pharmacology
Cabazitaxel
Cristian Villanueva, Fernando Bazán, Stefano Chong Hun Kim, Martin Demarchi, L. Chaigneau, Antoine Thiery-Vuillemin, Thierry Nguyen, L. Cals, Erion Dobi, Xavier B. Pivot · 2011 · Drugs
Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate
Charles J. Ryan, Eric Jay Small · 2005 · Journal of Clinical Oncology
Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts
Andrea S. Fung, Licun Wu, Ian F. Tannock · 2009 · Clinical Cancer Research
miR-138–Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics
Khalid Sossey‐Alaoui, Edward F. Plow · 2015 · Molecular Cancer Research
Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
Florian Rosar, Niklas Kochems, Mark Daniel Bartholomä, Stephan Maus, Tobias Stemler, Johannes Linxweiler, Fadi Khreish, Samer Ezziddin · 2021 · Cancers
Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment
Anis Hamid, Nicolas Sayegh, Bertrand F. TOMBAL, Maha Hussain, Christopher J. Sweeney, Julie Nicole Graff, Neeraj Agarwal · 2023 · American Society of Clinical Oncology Educational Book
[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617
Andrea Schaefer-Schuler, Caroline Burgard, Arne Blickle, Stephan Maus, Christine Petrescu, Sven Petto, Mark Daniel Bartholomä, Tobias Stemler, Samer Ezziddin, Florian Rosar · 2024 · Theranostics
Multi-faceted roles for CXC-chemokines in prostate cancer progression
David J J Waugh · 2008 · Frontiers in bioscience
A phase I study of TRC 105 anti‐endoglin ( CD 105) antibody in metastatic castration‐resistant prostate cancer
Fatima H. Karzai, Andrea Borghese Apolo, Liang Cao, Ravi Amrit Madan, David Eli Adelberg, Howard L. Parnes, David G. McLeod, Nancy Harold, Cody J. Peer, Yunkai Yu et al. · 2014 · British Journal of Urology
Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.
Tilman Todenhöfer, Jörg Hennenlotter, Susan Feyerabend, Stefan Aufderklamm, Johannes Mischinger, Ursula Kühs, Valentina Gerber, Jasmin Fetisch, David Schilling, Siegfried Hauch et al. · 2012 · PubMed
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer
Olivier Guérin, Patricia Formento, Cristiana Lo Nigro, Paul M Hofman, Jean–Louis Fischel, Marie-Christine Étienne-Grimaldi, Marco Carlo Merlano, J-M Ferrero, Gerard Alain Milano · 2007 · Journal of Cancer Research and Clinical Oncology
VEGF Inhibitors and Prostate Cancer Therapy
Jeanny B. Aragon‐Ching, William L. Dahut · 2009 · Current Molecular Pharmacology
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer
Jozsef Horti, Anders Widmark, Arnulf Stenzl, Miriam Hatsue Honda Federico, Raymond Pierre Abratt, Nick Sanders, Gillian M. Pover, I. Bodrogi · 2009 · Cancer Biotherapy and Radiopharmaceuticals
Comparison of Active and Passive Targeting of Docetaxel for Prostate Cancer Therapy by HPMA Copolymer–RGDfK Conjugates
Abhijit Ray, Nate Larson, Daniel B. Pike, Michele Grüner, Sachin Naik, Hillevi Bauer, Alexander Malugin, Khaled F. Greish, Hamidreza Ghandehari · 2011 · Molecular Pharmaceutics
New and emerging agents for the treatment of castration-resistant prostate cancer
Celestia S. Higano, E. David Crawford · 2011 · Urologic Oncology Seminars and Original Investigations
Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy
Gary G. Schwartz · 2008 · Annals of Epidemiology
Docetaxel rechallenge after an initial good response in patients with metastatic castration‐resistant prostate cancer
Stéphane Marie. Oudard, Gero Kramer, Orazio Caffo, Lorraine Creppy, Yohann Loriot, Steinbjørn Hansen, Mats Holmberg, Frédéric Rolland, Jean‐Pascal Machiels, Michael Krainer · 2014 · British Journal of Urology
Therapeutic options for hormone-refractory prostate cancer in 2007
Boris Alexander Hadaschik, Martin Edwin Gleave · 2007 · Urologic Oncology Seminars and Original Investigations
GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer
James Edward Ward, Douglas G. McNeel · 2007 · Expert Opinion on Biological Therapy
Cytotoxic Effects Induced by Docetaxel, Gefitinib, and Cyclopamine on Side Population and Nonside Population Cell Fractions from Human Invasive Prostate Cancer Cells
Murielle Mimeault, Sonny L. Johansson, Jean‐Pierre Hénichart, Patrick Depreux, Surinder K. Batra · 2010 · Molecular Cancer Therapeutics
Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration
Naoki Terada, Benjamin Louis Maughan, Shusuke Akamatsu, Takashi Kobayashi, Toshinari Yamasaki, Takahiro Inoue, Tomomi Kamba, Osamu Ogawa, Emmanuel S. Antonarakis · 2017 · International Journal of Urology
Prognostic Factors for Failure after Prostatectomy
Gregory P. Swanson, Joseph W. Basler · 2011 · Journal of Cancer
Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy
Ayako Ohtaka, Hiroaki Aoki, Masayoshi Nagata, Mayuko Kanayama, Fumitaka Shimizu, Hisamitsu Ide, Akira Tsujimura, Shigeo Horie · 2018 · Prostate International
Genetically Encoded Stealth Nanoparticles of a Zwitterionic Polypeptide-Paclitaxel Conjugate Have a Wider Therapeutic Window than Abraxane in Multiple Tumor Models
Samagya Banskota, Soumen Saha, Jayanta Bhattacharya, Nadia Kirmani, Parisa Yousefpour, Michael J. Dzuricky, Nikita Zakharov, Xinghai Li, Ivan Spasojević, Kenneth H. Young et al. · 2020 · Nano Letters
Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation
Wanling Xie, Meredith M. Regan, Marc E Buyse, Susan Halabi, Philip W. Kantoff, Oliver A. Sartor, Howard R. Soule, Donald A. Berry, Noel William Clarke, Laurence Collette et al. · 2020 · Journal of Clinical Oncology
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Elisabeth I. Heath, Melvin Gaskins, Henry Clement Pitot, Роберто Пили, Winston W. Tan, Robert Frederick Marschke, Glenn Liu, David W. Hillman, Fazlul H. Sarkar, Shijie Sheng et al. · 2005 · Clinical Prostate Cancer
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised Controlled Trial
Nicholas David James, Matthew Robert Sydes, Noel William Clarke, M. Mason, D.P. Dearnaley, J. Anderson, R. Popert, Karen Sanders, Rachel C. Morgan, J. Stansfeld et al. · 2008 · Clinical Oncology
Cooperative Dual-Activity Targeted Nanomedicine for Specific and Effective Prostate Cancer Therapy
Hung‐Wei Yang, Mu‐Yi Hua, Hao-Li Liu, Rung‐Ywan Tsai, Cheng‐Keng Chuang, Po‐Chun Chu, Pei‐Yi Wu, Ying‐Hsu Chang, Heng‐Chang Chuang, Kai‐Jie Yu et al. · 2012 · ACS Nano
A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone‐refractory prostate cancer
Thomas W. Flaig, Al Baha Barqawi, Gary J. Miller, Madeleine A. Kane, Chan X. Zeng, E. David Crawford, Leonard Michael Glodé · 2006 · Cancer
New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide
Florian Rosar, Sebastian Dewes, Martin Ries, Andrea Schaefer, Fadi Khreish, Stephan Maus, Hendrik Bohnenberger, Johannes Linxweiler, Mark Daniel Bartholomä, Carsten‐Henning Ohlmann et al. · 2020 · European Journal of Nuclear Medicine and Molecular Imaging
Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions
Rana R. McKay, Felix Yi-Chung Feng, Alice Y. Wang, Christopher J. D. Wallis, Kelvin A. Moses · 2020 · American Society of Clinical Oncology Educational Book
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Philipp E. Hartrampf, Franz‐Xaver Weinzierl, Andreas Konrad Buck, Steven P. Rowe, Takahiro Higuchi, Anna Katharina Seitz, Hubert R Kübler, Andreas Schirbel, Markus Essler, Ralph Alexander Bundschuh et al. · 2022 · European Journal of Nuclear Medicine and Molecular Imaging
Management of Prostate Cancer in Older Adults
Laura S Graham, John Kent Lin, Daniel E. Lage, Elizabeth Riley Kessler, Ravi Bharat Parikh, Alicia Katherine Morgans · 2023 · American Society of Clinical Oncology Educational Book
Frequent Gene Products and Molecular Pathways Altered in Prostate Cancer- and Metastasis-Initiating Cells and Their Progenies and Novel Promising Multitargeted Therapies
Murielle Mimeault, Surinder K. Batra · 2011 · Molecular Medicine
Engineered microenvironments provide new insights into ovarian and prostate cancer progression and drug responses
Daniela Loessner, Boris Michael Holzapfel, Judith Ann Clements · 2014 · Advanced Drug Delivery Reviews
Castration‐resistant prostate cancer: Many treatments, many options, many challenges ahead
Jorge Alberto Garcia, Brian I. Rini · 2011 · Cancer
Reduced incidence of bony metastasis at initial prostate cancer diagnosis: Data from CaPSURE™
Charles J. Ryan, Eric P. Elkin, Eric Jay Small, Janeen DuChane, Peter R. Carroll · 2006 · Urologic Oncology Seminars and Original Investigations
Adjuvant leuprolide with or without docetaxel in patients with high‐risk prostate cancer after radical prostatectomy (TAX‐3501)
Michael Thomas Schweizer, Peng Huang, Michael W. Kattan, Adam Stuart Kibel, Ronald de Wit, Cora Nanette Sternberg, Jonathan I. Epstein, Mario A. Eisenberger · 2013 · Cancer
Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes
Tomasz M. Beer, Bryan H. Goldman, Timothy Walter Synold, Christopher W. Ryan, Lakshmi Vasist, Peter J. Van Veldhuizen, Shaker R. Dakhil, Primo N. Lara, Anibal Drelichman, Maha Hussain et al. · 2008 · Clinical Genitourinary Cancer
Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer
Robert John Amato, Jaroslaw Jac, Taqi Mohammad, Somyata Saxena · 2008 · Clinical Genitourinary Cancer
Cancer Stem Cells in Prostate Cancer Chemoresistance
Jie Ni, Paul J. Cozzi, Jingli Hao, Wei Duan, Peter Graham, John Henry Kearsley, Yong Li · 2014 · Current Cancer Drug Targets